ZS 05

Drug Profile

ZS 05

Alternative Names: ZS05

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Zensun (Shanghai) Sci & Tech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Small cell lung cancer

Most Recent Events

  • 20 Jul 2016 Preclinical trials in Small cell lung cancer in China (unspecified route) (Zensun pipeline, July 2016)
  • 20 Jul 2016 ZS 05 is available for licensing as of 20 Jul 2016. http://www.zensunus.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top